• Hua Fang, Honglong Zhou, Jicai Zhang, Ziyi Li, Zhen Chen, RaoRao Yuan, Xiangqun Huang, Junyong Yang, Jianqiang Zhang, WangShuoSThe Second People's Hospital of Jingdezhen, Jingdezhen, China., Yong Huang, and Shangwei Hu.
• The Second Affiliated Hospital of Nanchang University, Nanchang.
• Medicine (Baltimore). 2020 Aug 28; 99 (35): e21929e21929.

BackgroundCerebral infarction (CI) is a common disease with high morbidity and disability. Shuxuetong (SXT) injection is a Chinese Materia Medica standardized product used in the treatment of CI. Currently, there is a lack of high-quality evidence to support the effectiveness and safety of SXT on patients with CI. This systematic review protocol aims at describing a meta-analysis to evaluate the efficacy of SXT for the treatment of CI.MethodsWe will search the databases of PubMed, MEDLINE, Embase, Cochrane Library Central Register of Controlled Trials, China national knowledge infrastructure database (CNKI), Wan fang database, Chongqing VIP information, and SinoMed from their inception to Jun 2020. Two reviewers will independently screen Randomized controlled trials of SXT for the treatment of CI. The meta-analysis will be conducted using RevMan V.5.3 software.ResultsThe results of this study will be published in a peer-reviewed journal.ConclusionThe conclusion of our systematic review will provide evidence to judge whether SXT is an effective intervention for patients with CI.Trial Registration Number10.17605/OSF.IO/3F6ZH.

22 keywords...

hide…